SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX) reported results from their preclinical study on the use of uncultured adipose-derived regenerative cells (ADRCs) in the treatment of critical periodontal defects in a rat model. The results suggest that the use of ADRCs may reverse the effects of periodontal disease, evidenced by significantly improved alveolar bone healing and decreased gingival (gum) invasion of the defect. The data were reported today at the 95th Annual Meeting of the American Academy of Periodontology in Boston.
